Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis
Open Access
- 20 January 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 20 (10), 1663-1673
- https://doi.org/10.1007/s00198-008-0825-6
Abstract
Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis.Keywords
This publication has 41 references indexed in Scilit:
- Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosisOsteoporosis International, 2007
- The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferationBiochemical Pharmacology, 2007
- Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelateCurrent Medical Research and Opinion, 2007
- Impact of Recent Fracture on Health-Related Quality of Life in Postmenopausal WomenJournal of Bone and Mineral Research, 2006
- The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal womenOsteoporosis International, 2005
- Reduced risk of back pain following teriparatide treatment: a meta-analysisOsteoporosis International, 2005
- Health care costs of women with symptomatic vertebral fracturesBone, 2004
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993